Single Anastomosis Versus Standard Duodenal Switch
Launched by LAVAL UNIVERSITY · Feb 21, 2021
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new surgical method for treating obesity, specifically a simplified version of a procedure called the Duodenal Switch. This new approach aims to help patients achieve significant weight loss and improve conditions like Type 2 Diabetes, which are often related to obesity. The trial will compare this new technique to the standard method to see which one works best for patients in the long run.
To participate in the trial, you need to be between 18 and 60 years old and have a body mass index (BMI) of 35 or higher, which means you are considered to have obesity. The research is currently looking for participants who are healthy enough for surgery and do not have certain medical conditions, like severe heart or liver disease, or a history of specific gastrointestinal issues. If you join the study, you will receive thorough medical evaluations and follow-ups to monitor your health and weight loss progress. This study could lead to important changes in how obesity is treated in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥18 years and ≤60 years
- • Fulfill criteria for bariatric surgery as coined by National Institutes of Health BMI≥35
- • Give written informed consent
- Exclusion Criteria:
- Participants who meet any of the following criteria at the time of the baseline visit are excluded from the study:
- * Presence of the following baseline comorbidities:
- • Inflammatory bowel disease (IBD),
- • Cirrhosis
- • History of gastric or duodenal ulcers
- • Preoperative hypoalbuminemia (\<35 g/L)
- • History of severe renal, hepatic, cardiac or pulmonary disease
- • Past esophageal, gastric or bariatric surgery
- • Type 1 Diabetes
- • Pregnancy
- • Evidence of psychological problem that may affect the capacity to understand the project and to comply with the medical recommendations
- • History of drug use or alcohol abuse in the last 6 months
- • History of gastro-intestinal inflammatory diseases
About Laval University
Laval University is a prestigious research institution located in Quebec, Canada, renowned for its commitment to advancing knowledge and innovation in various fields, including health sciences. The university actively engages in clinical trials aimed at exploring new therapeutic interventions and improving patient outcomes. With a strong emphasis on ethical standards and rigorous scientific methodologies, Laval University collaborates with multidisciplinary teams of researchers, healthcare professionals, and industry partners to conduct high-quality clinical research. Its state-of-the-art facilities and dedication to fostering a culture of inquiry position Laval University as a leader in clinical research, contributing significantly to the understanding and treatment of diverse medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Quebec City, Quebec, Canada
Patients applied
Trial Officials
Laurent Biertho, MD
Principal Investigator
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials